BioSpace News Archive

FDA

FDA Approves Sanofi and Regeneron’s Dupixent for Asthma

The FDA approved Sanofi and Regeneron’s Dupixent (dupilumab) as an add-on maintenance therapy for patients with moderate-to-severe asthma. The approved group is age 12 years and older with either an eosinophilic phenotype or with an oral corticosteroid-dependent asthma.

October 22, 2018
·
3 min read
·
Mark Terry
Drug Development

ESMO 2018: BMS’ Opdivo Shines in Renal Cell Carcinoma Results

A combination of Opdivo and Yervoy yielded a significantly longer treatment-free survival period for patients with previously untreated advanced or metastatic renal cell carcinoma (RCC) than patients who were treated with sunitinib, the standard of care.

October 22, 2018
·
2 min read
·
Alex Keown
Business

With Goals to Combat Antibiotic Resistance, Qpex Biopharma Launches with $33M

Qpex Biopharma, a company spun-out of The Medicines Company focused on the development of anti-infective assets, launched this morning supported by a $33 million Series A financing round and a BARDA contract worth up to $132 million.

October 22, 2018
·
2 min read
·
Alex Keown
Secarna Pharmaceuticals to attend BIO-Europe® 2018 - 24th Annual International Partnering Conference

Secarna Pharmaceuticals today announced that the Company will participate in the upcoming BIO-Europe®2018 – 24th Annual International Partnering Conference taking place from November 5 to 7, 2018 in Copenhagen, Denmark.

October 22, 2018
·
2 min read
Business

Department of Defense Amyotrophic Lateral Sclerosis Research Program

Anticipated Funding Opportunities for Fiscal Year 2019 (FY19)

October 22, 2018
·
4 min read
Business

Arjo to divest low-spec medical beds business

Arjo today signed an agreement to divest Acare – the group’s low-spec medical beds business – to China-based CBL Group. The divestment is a key part of the group’s action plan to improve profitability in the medical beds product category.

October 22, 2018
·
2 min read
Oventus Medical Ltd (ASX:OVN) New Clinical Trial Data Demonstrates Sleep Treatment Platform Delivers Significantly Improved Treatment Outcomes for OSA Sufferers

Oventus Medical Ltd is pleased to announce that new clinical data from four separate studies on its Sleep Treatment Platform will be presented at Sleep DownUnder, the 30th annual meeting of sleep specialists, taking place in Brisbane between 17th -20th October.

October 22, 2018
·
3 min read
Biotech Bay

Synthego Snags $110 Million in Series C to Advance Vision of Making CRISPR Technology More Available

Genome engineering company Synthego received an infusion of $110 million from a Series C financing round led by Peter Thiel’s Founders Fund. The funds will be used to accelerate the company’s vision to make CRISPR technology more accessible to researchers.

October 22, 2018
·
3 min read
·
Alex Keown
Drug Development

Updated with Exclusive | ESMO 2018: 60% of Ovarian Cancer Patients Receiving Lynparza Were Progression-Free at 3 Years

AstraZeneca and Merck & Co. presented results at the Presidential Symposium at the European Society for Medical Oncology 2018 Congress held in Munich Germany describing its Phase III SOLO-1 trial of Lynparza (olaparib) in ovarian cancer.

October 22, 2018
·
4 min read
·
Mark Terry
Business

Cc develops the brand Joyn Bio for the newly formed joint venture of Ginkgo Bioworks and Leaps by Bayer

Brand, name, CI and website for Joyn Bio created by Cc – Circle Culture Consulting. The core task consisted of finding the appropriate visual language to communicate the innovations of the new synthetic biology company.

October 22, 2018
·
2 min read